The increasing understanding of FTD’s complex pathophysiology, involving molecular subtypes such as FTLD-tau and FTLD with TDP-43 pathology,49 highlights the importance of precise data to support advancements in both pharmacological and nonpharmacological treatments. This evidence concerns the gene MAPT and frontotemporal dementia.